Article and Video CATEGORIES

Cancer Journey

Search By

Understanding how tumors respond to radiation has been a lifelong process for Puneeth Iyengar, M.D., Ph.D., Assistant Professor of Radiation Oncology at UT Southwestern Medical Center. He began testing theories in school science fairs as an adolescent growing up in Louisiana. Studying at MIT furthered his interest in the biologic and engineering aspects of medicine, and he earned a bachelor of science degree in biology before receiving his M.D./Ph.D. degrees from Albert Einstein College of Medicine in New York in 2005.

Lung Cancer Video Library 2025
AlexandraGBeneke
As part of the 2025 Lung Cancer Video Library, where oncologists discuss the most emerging treatment options and informatIon in lung cancer, Dr. Puneeth Iyengar (Memorial Sloan Kettering Cancer Center) discusses when to consider radiation and/or surgery in the management of advanced non-small cell lung cancer (NSCLC) for survival benefit.
Author
Puneeth Iyengar, M.D., Ph.D., GRACE Faculty
Image
Lung Cancer video library 2025

In these video series, Dr. Iyengar discusses two indications, or timepoints, where radiation and/or surgery may be used to improve the survival outcomes in metastatic, non-small cell lung cancer (NSCLC) patients, specifically focusing on consolidation. He discusses various trials, but also the importance of how radiation would help patients who were receiving immunotherapy-based regiments. This led to the discussion of NRG-LU002, a randomized phase II/III trial of maintenance systemic therapy vs. local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).

He also  discusses how biology affects non-small cell lung cancer (NSCLC) outcomes,  the results of NRG-LU002, a randomized phase II/III trial of maintenance systemic therapy vs. local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC), and how to select patients for the optimal therapy for metastatic non-small cell lung cancer (NSCLC).

To watch the complete playlist, click here.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on